Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where did you read they couldn’t prove abuse deterrence?
According to this article, Teva and Endo have already received approval, but haven’t launched, but was written years ago, but was recently republished:
https://www.inquirer.com/archive/oxycontin-generic-approval-fda-endo-tevin-20040325.html
Q will be out by mid-Feb. Requirements haven’t changed and should be filed to SEC by 2/15. CC will be day after.
Did you see Nasrat file a form 4 selling shares? SEC isn’t posting it so I’m guessing you have exclusive rights to fake form 4’s.
I remember years ago being told by a broker that the OTC is like the Wild West. It doesn’t follow similar requirements as exchanges. Take that for what it’s worth.
Since they won’t be shifting to calendar fiscal year for some timed, the Q is due mid-Feb for Q3 reporting.
We have no idea how many others filed, whether first to file has any benefit in this case + branded drug is always part of the competition, but less so as more enter the market.
Even being among the first will be fantastic, but still not a billion dollar market that I commented on.
Love the comments. Just a reminder that generic oxy is <$1B.
Payable is settled with the acceptance of shares in lieu of cash back at time of service rendered.
According to one of links provided, he lives in same household as her.
And married to Nasrat?
I think we’ll see similar payment in shares cleanup for the next 6 months.
Every state differs from tax standpoint. I thought you meant impact to the actual SS gross amount. Income is taxed from laddered standpoint. More you make, more you are taxed by fed, state, counties/cities depending where you live.
No consequences if you keep working. If get benefits through work you most likely can delay Medicare Part B premium too, but not for really small companies.
For years you don’t qualify for a Roth, there is the backdoor Roth option. So there’s always the Roth option regardless of income levels.
This ties to my comments that the market value (numerator) will drastically decrease. Will not be $5B when we launch.
Yes, but the numerator will certainly change near term, but should have solid long term growth along with rest of CNS profile.
I think over 10
Merry Christmas ELTP gang. We may not agree on leadership, we may not agree on growth trajectory, etc. I appreciate the dialogue. Enjoy this special day. Here’s to a solid 2024 for us all.
100% agree. I’d consider ADT success icing, on the icing already on the cake. The likelihood is very small and highly doubt they will allocate resources after getting burned. Elite has great trajectory as is.
Let’s not put words in the FDAs mouth with unapproved technology. Nasrat’s had given no hint that Elite is moving forward with SequestOx v2, even if they had the funds.
No, but they battle the same economic headwinds. Market doesn’t want ADF dude. Get real. You can fake it all you want, but reality doesn’t dissolve into the ether.
I’d really like to keep you muted but I can see your ridiculous posts for some reason. Will try once again.
If FDA decreases non ADF quota? Come on. If FDA was to do this they would have done it years ago when opioid crisis was front page news on regular basis with Purdue in limelight. Not happening.
Here comes the applesauce. SequestOx is dead.
Are you completely ignorant? CEO himself said it was shelved.
I don’t need a quote. I know what he said. Scripts aren’t always accurate either. Not worth my time. You will see though all in good time.
He said there was a lack of market for ADT. This means the market doesn’t accept the premium pricing needed above common generic. So you can understand in simplest forms. There will be no feasible revenue or profitability by pursuing the treadmill of ADT they thought SequestOx would open up.
It’s relative and data is several years old. I’d like to see cost comparison today.
CEO stated market didn’t exist for higher ADT pricing. Go back and read the transcripts. SequestOx is a sunk cost. Not being pursued until both FDA and market shifts. It’s all pricing dude.
Yes, they noted their tech was cheaper many years ago. It’s all relative. They also stated demand didn’t exist either. If larger companies can push FDA towards ADT, then fantastic. Elite couldn’t do it on their own. This is the primary reason the company has massive bloat.
SequestOx is shelved buddy. Give it up. You can go back to your government cube now and pretend like world is out against you.
Nothing beyond one day’s liquidity to cover. Nothing material here.
Someone is also at this time putting hamsters up their rear end. Doesn’t mean there is a big market for it. Many more drugs being abused than CNS drugs. CEO has stated that the market can’t support premium for abuse deterrence at reasonable levels. Price is the major factor for providers to select a drug for a patient. Until the FDA actually makes a move towards ADT, common generics will continue to win out. We are playing in this space, are doing fantastic and will continue to have a bright future. I highly doubt an ADT will be approved prior to being acquired.
Each of the drugs in generic form have nothing to do with ADT. Timed release is not ADT. Their tech has not been applied to the CNS drugs. As CEO has stated, SequestOx with the ADT tech has been shelved due to cost, lack of market, etc.
There is no pipeline here. Elite’s tech has been shelved due to both demand, price and cost issues. Elite is a generic, not ADT focused company.
Far too early for buyout to be acceptable for shareholders. I could see it in 2+ years.
The timing of the acceptance isn’t up to Elite. It’s up to the FDA. The timing for when Elite has to file a PR for the acceptance isn’t up to Elite either. That’s per SEC guidelines. None of this has to do with being bogged down with the lawsuit. This is a reporting requirement as a publicly held company.
Third time’s the charm. :)
Wrong board
Why would it not be good? We just launched with Prasco/Burel. I think your penny lift is underestimated based on momentum of the company and what’s in near term pipeline.